Franklin Resources Inc. Takes $17.66 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Franklin Resources Inc. purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 720,547 shares of the company’s stock, valued at approximately $17,661,000. Franklin Resources Inc. owned approximately 2.06% of Oruka Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ORKA. FMR LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $114,763,000. RTW Investments LP acquired a new position in Oruka Therapeutics during the third quarter valued at approximately $45,359,000. Braidwell LP bought a new stake in Oruka Therapeutics during the third quarter worth $12,640,000. Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $12,614,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $11,822,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $20.31 on Friday. Oruka Therapeutics, Inc. has a 52 week low of $18.20 and a 52 week high of $53.88. The company has a fifty day moving average price of $24.55. The company has a market cap of $710.83 million, a price-to-earnings ratio of -3.24 and a beta of 0.78.

Analyst Ratings Changes

ORKA has been the subject of several recent analyst reports. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday. Finally, Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.